

Regeneron Pharmaceuticals, Inc. (REGN)

Healthcare / Biotechnology · NASDAQ Global Select

Generated: 2026-Oct-18 · Market data through: 2026-10-16

LAST CLOSE \$790.74 2026-10-16	MARKET CAP \$81.4B VOLUME 0.7M	52-WK HIGH \$859.34 52-WK LOW \$566.11	TRAILING PE 18.9 P/S 5.24	GROSS MARGIN 84.9% NET MARGIN 27.9%	ROE 14% ROIC 9%	PIOTROSKI 7/9 ALTMAN Z 7.3	1-YR RETURN +39.1% 5-YR RETURN +168.6%
---	---	---	--	--	--	---	---

Regeneron Pharmaceuticals, Inc. is a global biopharmaceutical enterprise focused on discovering, inventing, developing, manufacturing, and bringing to market medical treatments for a wide array of illnesses. Its therapeutic portfolio includes EYLEA, an injection used to treat various ophthalmic conditions such as wet age-related macular degeneration, diabetic macular edema, myopic choroidal neovascularization, diabetic retinopathy, and macular edema resulting from retinal vein occlusion (both central and branch). Other significant offerings are Dupixent, an injectable solution for atopic dermatitis and asthma in both adults and pediatric patients; Libtayo, indicated for metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent, an injection prescribed for adults with heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease; REGEN-COV for COVID-19; and Kevzara, a solution targeting rheumatoid arthritis in adult patients. Furthermore, Regeneron provides Imzabz for infections caused by Zaire ebolavirus; ARCALYST, an injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and Muckle-Wells syndrome; and ZALTRAP, an intravenous infusion used in the treatment of metastatic colorectal cancer. In addition to its existing product lineup, the company is actively engaged in developing novel product candidates aimed at addressing unmet medical needs in areas such as ocular diseases, allergic and inflammatory conditions, cardiovascular and metabolic disorders, infectious diseases, rare diseases, cancer, pain management, and hematologic conditions. Regeneron maintains extensive collaboration and licensing agreements with a diverse range of partners, including Sanofi, Bayer, Teva Pharmaceutical Industries Ltd., Mitsubishi Tanabe Pharma Corporation, Alnylam Pharmaceuticals, Inc., Roche Pharmaceuticals, and Kiniksa Pharmaceuticals, Ltd. It also holds agreements with entities such as the U.S. Department of Health and Human Services, Zai Lab Limited, Intellia Therapeutics, Inc., the Biomedical Advanced Research Development Authority, and AstraZeneca PLC. The company was founded in 1988 and its corporate headquarters are situated in Tarrytown, New York.

SECTOR Healthcare INDUSTRY Biotechnology EXCHANGE NASDAQ MARKET CAP \$81.4B EMPLOYEES 15,410 (SEC-filed) CEO Leonard S. Schleifer IPO 1991-04-02
COUNTRY US
777 Old Saw Mill River Road, Tarrytown, NY 10591-6707 · Tel 914 847 7000 · [regeneron.com](https://www.regeneron.com)

1 INSIDERSTREET SCORE

INSIDERSTREET SCORE

68 / 100

Street mean **\$849.39** (18 analysts, last qtr) — their number, not ours

INSIDER CONSENSUS SIGNAL


ROUTINE SELLING — LOW SIGNAL

\$7M sold / 6 mo, zero open-market buys


2 PRICE AND VOLUME

adjusted close, prod data layer

1 Year vs S&P 500 · **REGN +39.1%** · **S&P 500 +15.9%** · spread **+23.2pp**



7 Years vs S&P 500 · **REGN +168.6%** · **S&P 500 +189.9%** · spread **-21.3pp**



Both charts indexed to 100 at the start of their window and drawn on a single shared scale, so the gap to the benchmark is the gap you see. Adjusted closes throughout.

THIS SPACE INTENTIONALLY LEFT BLANK — THE NEXT SECTION BEGINS ON THE FOLLOWING PAGE

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

3 INSIDERSTREET SCORE

live IS factor model

INSIDERSTREET
SCORE

68

OF 100

Score Breakdown

Profitability	82/100
Growth	45/100
Momentum	67/100
Quality	85/100
Earnings Quality	68/100
Balance Sheet	97/100
Value	69/100
Risk (safety)	100/100
Overall	68.4/100

Each component is a diagnostic reading on its own 0-100 scale. The overall score is computed separately from the underlying financials and is **not** the average of the rows above — components are not equally weighted and three of them (Momentum, Value, Risk) are derived partly from price rather than from the business.

Peer Comparison — IS Score

SYMBOL	IS SCORE
MRNA	30
VRTX	76
ARGX	74
ONC	78
ALNY	68
ROIV	38
REGN	68

IS Score Trend — quarterly



4 TWO READINGS

business vs price

BUSINESS QUALITY

68 / 100

IS Score 68.4 / 100 · -5.1 from peak of 73

Quarter	Business Quality
23 Q1	52
23 Q2	58
23 Q3	65
23 Q4	68
24 Q1	68
24 Q2	62
24 Q3	68
24 Q4	72
25 Q1	73
25 Q2	73
25 Q3	70
25 Q4	68
26 Q1	68

Fundamental factor model, quarterly. Measures how the business is doing - not where the price is going.

PRICE STRUCTURE

BULLISH

Technical Score 76 / 100 · Power +51 · 21 of 22 indicator votes bullish

Date	Price Structure
07-23	38
08-13	105
09-03	105
09-25	38
10-16	76

Vote share across trend, momentum, volume, volatility and pattern families. Describes where the price is, not where it is going.

Both readings sit above the midpoint — business quality at 68 and price structure at 76 out of 100 — so they are not in conflict. The fundamentals and the tape are saying the same thing, which is the case in which either one alone would have been enough.

5 WHAT WOULD CHANGE OUR MIND

falsifiable - check us next quarter

TRIGGER	WHERE IT STANDS NOW	WHAT IT WOULD MEAN
IS Score reaches 75 and holds two consecutive quarters	now 68.4	would move us up one band
IS Score stops falling - one quarter higher than the prior	last four: 72 → 69 → 71 → 68	the direction matters more than the level
Technical vote share back above 50%	now 91%	price structure no longer broken
Institutional holder count rises two quarters running	peak 1,398 → now 1,340	fewer institutions willing to hold is our clearest warning

We publish these so the view can be shown to be wrong. If none of them move and our reading does, we owe you an explanation.

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

This page is InsiderStreet's own reading, produced from the data in the rest of this document. It is not a price target and not investment advice. Analyst consensus and street price targets appear later under their own heading and are the street's numbers, not ours.


6 SMART MONEY CONFLUENCE EDGE · disclosure sources

SITE CONVERGENCE SCORE 3 of 4 top 4% of 29,420 symbols	SOURCES ALIGNED — of 3 independent disclosures	CONGRESS (180D) 2 buys 2026-07-07	INSIDER BUYS (180D) 0 none disclosed
ETF FUNDS (30D) 1489 up / 1361 down net +128 funds	INSTITUTIONS ADDED (13F) -58 managers opening or increasing		

Congressional and insider figures are disclosed purchases in the trailing 180 days; ETF figures are COUNTS OF FUNDS whose holding changed in 30 days, not dollars. Coincidence of separate disclosures, not coordination. An absent source means nothing qualifying was disclosed in its window.

7 INSTITUTIONAL OWNERSHIP - 12-QUARTER TREND 13F · filed 45 days after quarter end

Institutions holding — 12 quarters



Peak 1,398 · latest 1,340 (-58 from peak).

QUARTER	HOLDERS	13F SHARES	VALUE	REPORTED OWN%
2026 Q2	1,340	92.3M	\$55.7B	89.3%
2026 Q1	1,398	88.8M	\$66.2B	85.9%
2025 Q4	1,382	89.9M	\$66.8B	87.0%
2025 Q3	1,240	87.1M	\$47.8B	84.2%
2025 Q2	1,201	89.5M	\$46.2B	86.5%
2025 Q1	1,287	93.3M	\$56.4B	90.3%
2024 Q4	1,313	93.5M	\$63.6B	90.4%
2024 Q3	1,387	93.9M	\$94.3B	90.8%
2024 Q2	1,327	94.2M	\$96.2B	91.1%
2024 Q1	1,310	93.3M	\$86.7B	90.2%
2023 Q4	1,267	91.3M	\$78.3B	88.3%
2023 Q3	1,171	90.9M	\$71.8B	87.9%

How to read ownership above 100%. A 13F reports the positions a manager has investment discretion over, and where two or more managers share discretion over the same block, each one reports it. Summed across filers, the total can therefore exceed the shares actually outstanding without anything being wrong. We publish the figure as filed rather than netting it down, and flag separately any quarter where the arithmetic is not merely high but impossible.

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY


8 INSIDER ACTIVITY live Form 4 data

INSIDER	ROLE	DATE	TYPE	SHARES	VALUE	POST-TXN OWNED
Murphy Andrew J	Co-Chief Scientific Officer	2026-10-14	SELL	6	\$0.00M	51,974
Murphy Andrew J	Co-Chief Scientific Officer	2026-10-14	SELL	35	\$0.03M	51,939
Murphy Andrew J	Co-Chief Scientific Officer	2026-10-14	SELL	16	\$0.01M	51,923
Murphy Andrew J	Co-Chief Scientific Officer	2026-10-14	SELL	24	\$0.02M	51,899
Murphy Andrew J	Co-Chief Scientific Officer	2026-10-14	SELL	14	\$0.01M	51,885
Murphy Andrew J	Co-Chief Scientific Officer	2026-10-14	SELL	74	\$0.06M	51,811
Murphy Andrew J	Co-Chief Scientific Officer	2026-10-14	SELL	27	\$0.02M	51,784
Murphy Andrew J	Co-Chief Scientific Officer	2026-10-14	SELL	55	\$0.04M	51,729

9 SELL DECOMPOSITION — ROUTINE VS. DISCRETIONARY EDGE

6-MO DECOMPOSITION (FORM 4)	TXNS	SHARES	VALUE	SIGNAL WEIGHT
S — Open-market sales	67	8,593	\$6.9M	Counted
M — Exercises (paired A/D)	6	37,165	\$14.5M	None — mechanics
F — Tax withholding	3	26,471	\$20.9M	None — compensation
P — Open-market purchases	0	0	\$0	Counted — none occurred

Monthly Net Insider Flow (000 shares)



Net of acquisitions minus dispositions, all Form 4 types.

Signal Summary

SIGNAL Routine Selling — Low Signal	OPEN-MARKET SELLS \$6.9M 67 txns / 6 mo	OPEN-MARKET BUYS \$0.0M 0 txns / 6 mo	CLUSTER None active 3+ insiders / 21 days
--	---	---	---

10 FORM 144 PLANNED-SALE PIPELINE live EDGAR data

FILED	FILER	SHARES REGISTERED	EST. PROCEEDS
2026-10-14	Murphy Andrew J	4,147	\$3.2M
2026-08-10	Zoghbi Huda Y	800	\$0.6M
2026-08-10	Guarini Kathryn	400	\$0.3M
2026-07-02	Arthur F. Ryan	400	\$0.2M
Trailing 12 mo	11 filings	19,012	\$14M

11 13D / 13G STAKES COND

FILED	FORM	REPORTING PERSON	% OF CLASS	SHARES
2026-04-30	SCHEDULE 13G	Vanguard Capital Management	7.37%	7.7M sh
2026-03-27	SCHEDULE 13G/A	The Vanguard Group	—	exit/reporting change
2025-08-06	SCHEDULE 13G/A	Abigail P. Johnson	3.20%	3.4M sh
2025-06-05	SCHEDULE 13G/A	JPMORGAN CHASE & CO.	4.40%	4.7M sh

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

12 CONGRESSIONAL TRADING					EDGE · STOCK Act
MEMBER	CHAMBER	TRADE	SIZE BAND	TRADED	DISCLOSED
Ro Khanna	House	SELL	\$1,001 - \$15,000	2026-09-04	2026-10-09
Ro Khanna	House	BUY	\$1,001 - \$15,000	2026-07-07	2026-08-12
Gilbert Cisneros	House	SELL	\$1,001 - \$15,000	2026-05-15	2026-06-09
Alan Armstrong	Senate	BUY	\$1,001 - \$15,000	2026-03-27	2026-07-21
Tommy Tuberville	Senate	SELL	\$1,001 - \$15,000	2024-04-04	2024-05-15
Tommy Tuberville	Senate	SELL	\$1,001 - \$15,000	2024-04-04	2024-05-14
HOUSE 12-MO 11 trades 6 purchases		SENATE 12-MO 1 trades 1 purchases		COVERAGE STOCK Act filings 30-45 day disclosure lag	

13 INSTITUTIONAL OWNERSHIP & 13F FLOW				live 13F data
13F FILERS (LAST COMPLETE Q) 1,398	13F SHARES 89M 85.9% of shares out	NEW / CLOSED 141 / 98 positions, QoQ	INCREASED / REDUCED 578 / 458 positions, QoQ	
PUT/CALL (13F) 0.88 option positions	FREE FLOAT 96.2% 99M sh			

2.8 · Largest Reporting 13F Managers


MANAGER	SHARES	VALUE
Jia Investment Alliance Pte. Ltd.	67,300	\$51M
Atwood & Palmer Inc	42,454	\$32M
Fjarde Ap-Fonden /Fourth Swedish N	40,105	\$30M
Wealth Enhancement Advisory Servic	37,200	\$20M
Assenagon Asset Management S.A.	36,881	\$28M
Wedge Capital Management L L P/Nc	33,733	\$26M

EDGAR 13F holdings as of 2026-09-30; filer values normalized to dollars.


2.9 · Top ETF & Fund Ownership

FUND	WEIGHT	POSITION
VITSX	0.1%	\$2.4B
VTSAX	0.1%	\$2.4B
VSMPX	0.1%	\$2.4B
VTI	0.1%	\$2.4B
VOO	0.1%	\$2.0B
VFIAX	0.1%	\$2.0B

13F Filers Holding REGN — quarterly



Institutional Put/Call — quarterly




THIS SPACE INTENTIONALLY LEFT BLANK — THE NEXT SECTION BEGINS ON THE FOLLOWING PAGE

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

14 SHORT VOLUME — DAILY, 60 SESSIONS

EDGE · live FINRA feed




Daily short-sale volume as % of volume reported in FINRA's short-sale file — a flow measure, not short interest; dashed = 50-day average.

LATEST SESSION 50.0% 2026-10-15	20-DAY AVG 47.4% 50-day 51.1%	TREND Falling 20d vs 50d	BY MARKET CENTER Q: 50% · N: 62% · B: 25% latest session
--	--	---------------------------------------	---

15 DARK POOL ACTIVITY

EDGE · live ATS data




Where REGN Trades in the Dark

ATS VENUE (4-WK)	SHARES	AVG TRADE
Incr Intelligent Cross Llc	0.9M	20 sh
Ubsa Ubs Ats	0.7M	22 sh
Sgmt Sigma X2	0.5M	18 sh
Mlix Instinct X	0.4M	29 sh
Ebxl Level Ats	0.3M	11 sh
Cgxs Onechronos	0.3M	31 sh

16 REVENUE FLOW — FY2025

live segmentation + income data



Where a dollar of Regeneron Pharmaceuticals, Inc. revenue goes. All values FY2025 filings, live.

17 GEOGRAPHIC REVENUE

live segmentation

REGION	REVENUE	SHARE
UNITED STATES	\$4.4B	90%
Rest Of World	\$508M	10%


THIS SPACE INTENTIONALLY LEFT BLANK — THE NEXT SECTION BEGINS ON THE FOLLOWING PAGE

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY


18 MOAT & COMPETITIVE POSITION

LIVE MODEL · 55/100 NARROW

Moat score 55/100 — Narrow; primary source Switching Costs.



3.8 · Employees (SEC filings)




19 CORPORATE INFORMATION — KEY OFFICERS

15,410 employees

OFFICER	TITLE
Leonard S. Schleifer	Co-Founder, President, Chief Executive Officer & Co-Chairman
George D. Yancopoulos	Co-Founder, President, Chief Scientific Officer & Co-Chairman
Joseph J. LaRosa	Executive Vice President, General Counsel & Secretary
Daniel Van Plew	Executive Vice President and GM of Industrial Operations & Product Supply

20 REVENUE & EPS — HISTORY AND ESTIMATES

live consensus




Actual bars are GAAP diluted EPS from the filed income statement; the lighter forward bars are street-basis consensus. The two are different measures and are not comparable quarter to quarter.

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

21 ESTIMATE VS. ACTUAL & SURPRISES

live data



22 REPORTED VS. CONSENSUS — FULL HISTORY

0 quarters · live data


BEAT RATE —% 0 of 0 quarters	CURRENT STREAK 0 longest 0	AVG EPS SURPRISE —% median —%	SURPRISE TREND — last 4 vs prior 4
------------------------------------	----------------------------------	-------------------------------------	--

PERIOD	EPS EST.	EPS ACTUAL	EPS SURPRISE	REV EST. (\$M)	REV ACTUAL (\$M)	REV SURPRISE
--------	----------	------------	--------------	----------------	------------------	--------------

Announcement dates to . Consensus as it stood at each report. Revenue surprise shown where both estimate and actual are filed. A beat record is history, not a forecast.


INCOME TRENDS — 5 YEAR

live financials



NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Revenue by Segment — Stacked



Live segmentation data.

YoY Growth Heatmap — Income Lines

YOY GROWTH	FY21	FY22	FY23	FY24	FY25
Revenue	+89.1%	-24.3%	+7.8%	+8.3%	+1.0%
Gross profit	+86.9%	-21.6%	+3.9%	+12.5%	+0.1%
Operating income	+150.1%	-39.8%	-19.3%	-8.2%	-10.3%
Net income	+129.9%	-46.3%	-8.9%	+11.6%	+2.1%


23 INCOME STATEMENT — FULL

live financials

\$B · FY ENDS	FY21	FY22	FY23	FY24	FY25	TREND
Revenue	16.1	12.2	13.1	14.2	14.3	
Cost of revenue	2.7	1.7	2.2	2.0	2.1	
Gross profit	13.3	10.5	10.9	12.2	12.2	
R&D expense	2.6	3.1	4.0	5.2	5.9	
SG&A expense	1.8	2.1	2.5	3.0	2.7	
Operating income	8.9	5.4	4.3	4.0	3.6	
EBITDA	9.7	5.3	4.7	5.3	5.8	
D&A	0.3	0.3	0.4	0.5	0.5	
Pretax income	9.3	4.9	4.2	4.8	5.2	
Income tax	1.3	0.5	0.2	0.4	0.7	
Net income	8.1	4.3	4.0	4.4	4.5	
Diluted EPS (\$)	71.97	38.22	34.77	38.34	41.48	
Diluted shares (M)	112	114	114	115	109	

CASH FLOW TRENDS


live data



NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

WHERE THE CASH WENT — FY2025

cash Sankey, live data



Balance Sheet — Full


\$B	FY22	FY23	FY24	FY25	
Cash & equivalents	3.1	2.7	2.5	3.1	
ST investments	4.6	8.1	6.5	5.5	
Receivables (net)	5.3	5.7	6.2	5.7	
Total current assets	15.9	19.5	18.7	18.0	
PP&E (net)	3.8	4.1	4.6	5.1	
Goodwill + intangibles	0.9	1.0	1.1	1.3	
Total assets	29.2	33.1	37.8	40.6	
Accounts payable	0.6	0.6	0.8	0.9	
Short-term debt	0.0	0.0	0.0	0.0	
Deferred revenue	0.5	0.5	0.6	0.6	
Total current liabilities	3.1	3.4	3.9	4.4	
Long-term debt	2.0	2.0	2.0	2.0	
Total liabilities	6.6	7.1	8.4	9.3	
Shareholders' equity	22.7	26.0	29.4	31.3	

Cash Flow Statement — Full

\$B	FY22	FY23	FY24	FY25	
Net income	4.3	4.0	4.4	4.5	
D&A	0.3	0.4	0.5	0.5	
Stock-based compensation	0.7	0.9	1.0	1.0	
Working capital change	(0.2)	(0.1)	(0.6)	0.5	
Operating cash flow	5.0	4.6	4.4	5.0	
Capital expenditures	(0.6)	(0.9)	(0.8)	(0.9)	
Investing cash flow	(3.8)	(3.2)	(2.5)	(0.6)	
Buybacks	(2.5)	(2.9)	(3.6)	(3.4)	
Dividends paid	0.0	0.0	0.0	(0.4)	
Debt issuance / (repay)	0.0	0.0	0.0	0.0	
Financing cash flow	(1.0)	(1.8)	(2.2)	(3.7)	
Free cash flow	4.4	3.7	3.7	4.1	

THIS SPACE INTENTIONALLY LEFT BLANK — THE NEXT SECTION BEGINS ON THE FOLLOWING PAGE

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY



24 EXPANDED RATIO ANALYSIS (I)

live ratio engine · profitability · valuation

RATIO	FY21	FY22	FY23	FY24	FY25	TTM	TREND
PROFITABILITY							
ROE	54.2%	20.9%	16.3%	16.0%	14.9%	14%	
ROA	37.9%	15.9%	12.7%	12.5%	11.5%	10.4%	
ROIC	49.1%	26.0%	22.6%	16.0%	12.2%	9.2%	
Gross margin	83.1%	86.0%	82.9%	86.1%	85.4%	84.9%	
Operating margin	55.7%	44.2%	33.2%	28.1%	24.9%	25.6%	
Net margin	50.2%	35.6%	30.1%	31.1%	31.4%	27.9%	
EBITDA margin	60.2%	43.2%	35.8%	37.4%	40.6%	37.0%	
FCF margin	40.6%	36.3%	29.1%	25.3%	28.4%	—	
VALUATION							
P/E	8.80	18.85	25.14	18.27	18.42	18.9	
P/B	3.79	3.61	3.83	2.75	2.65	2.6	
P/S	4.42	6.72	7.58	5.68	5.79	5.24	
P/FCF	10.89	18.49	26.07	22.41	20.33	23.1	
EV/EBITDA	7.04	14.59	19.44	13.97	13.25	14.1	
EV/Revenue	4.24	6.31	6.96	5.23	5.37	5.2	
Earnings yield	11.4%	5.3%	4.0%	5.5%	5.4%	5.29%	
FCF yield	9.2%	5.4%	3.8%	4.5%	4.9%	4.33%	

EXPANDED RATIO ANALYSIS (II)

leverage · solvency

RATIO	FY21	FY22	FY23	FY24	FY25	TTM	TREND
LEVERAGE & SOLVENCY							
Current ratio	3.56	5.06	5.69	4.73	4.13	3.34	
Quick ratio	3.07	4.29	4.94	3.95	3.39	2.78	
Debt / equity	0.14	0.12	0.10	0.09	0.09	0.06	
Debt / assets	10.6%	9.2%	8.2%	7.2%	6.7%	4.8%	
Net debt / EBITDA	-0.31	-0.96	-1.73	-1.19	-1.01	-0.08	
Interest coverage	163.75	82.80	58.52	87.59	120.42	—	

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

EXPANDED RATIO ANALYSIS (III)							efficiency · growth · per-share · scores
RATIO	FY21	FY22	FY23	FY24	FY25	TTM	TREND
EFFICIENCY							
Asset turnover	0.75	0.45	0.42	0.40	0.37	0.37	
Receivables turnover	3.17	2.14	2.39	2.39	2.40	2.4	
DSO (days)	115	170	153	153	152	154	
DPO (days)	70	119	98	129	150	180	
Cash conversion cycle	305	501	462	548	548	453	
GROWTH (YoY)							
Revenue growth	89.1%	-24.3%	7.8%	8.3%	1.0%	—	
Net income growth	129.9%	-46.3%	-8.9%	11.6%	2.1%	—	
EPS growth	127.9%	-46.7%	-8.7%	11.6%	8.1%	—	
FCF growth	225.9%	-32.2%	-13.8%	-5.7%	13.4%	—	
PER SHARE (\$)							
EPS (diluted, TTM)	71.34	38.06	34.74	38.78	41.91	41.86	
Book value / share	165.80	198.81	228.23	257.94	290.76	306.68	
Revenue / share	141.98	106.78	115.27	124.80	133.42	150.24	
FCF / share	57.68	38.81	33.51	31.61	37.96	34.06	
Cash / share	50.31	67.91	95.30	79.20	80.05	77.32	
SHAREHOLDER RETURN & SCORES							
Buyback yield	3.8%	3.1%	3.0%	3.9%	4.1%	4.95%	
Altman Z-Score	9.77	10.10	10.95	8.20	7.77	7.3	
Piotroski F-Score	5	6	7	8	5	7/9	
Beneish M-Score	-1.36	-2.71	-2.51	-2.24	-2.52	-2.31	

25 EARNINGS QUALITY PANEL				live scores
MODEL	SCORE	ZONE	NOTE	
Piotroski F-Score	7 / 9	Strong		
Altman Z-Score	7.3	Safe (>2.99)	Safe	
Income quality	1.03	Cash-backed	OCF ÷ net income	
Beneish M-Score	-2.31	Non-manipulator	vs -2.22 threshold	

26 DUPONT & GROWTH QUALITY				live analysis engine
DUPONT DECOMPOSITION (TTM)		VALUE	GROWTH QUALITY (LIVE)	VALUE
Tax burden		0.84	Revenue stability	0.87
Interest burden		0.99	Earnings stability	0.69
Operating margin		33.6%	Earnings persistence	0.99
Asset turnover		0.39×	Revenue CAGR 3y	7.0%
Financial leverage		1.30×	EPS CAGR 3y	2.4%
= ROE		14%	FCF CAGR 3y	-5.3%

THIS SPACE INTENTIONALLY LEFT BLANK — THE NEXT SECTION BEGINS ON THE FOLLOWING PAGE

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

SHAREHOLDER RETURN PROFILE live

BUYBACK YIELD 4.95%	DIVIDEND YIELD 0.47%	TOTAL SHAREHOLDER RETURN 4.38% cash yield	SBC / REVENUE 6.4% dilution pressure
------------------------	-------------------------	---	--

27 MULTIPLE HISTORY — FY SNAPSHOTS + TTM live ratio engine



28 PEER COMPARISON live peer engine

COMPANY	MKT CAP	P/E	ROE	NET MARGIN	REV GROWTH	PIOTROSKI	1-YR RET
MRNA	\$87.0B	-27.3	-39%	—	-27.2%	2/9	+758.6%
VRTX	\$126.7B	28.9	24%	33.0%	+10.6%	6/9	+22.3%
ARGX	\$51.5B	29.6	47%	29.8%	+242.1%	5/9	-2.2%
ONC	\$39.4B	25.6	15%	13.9%	+34.3%	8/9	+16.0%
ALNY	\$31.0B	38.0	101%	12.7%	+95.1%	6/9	—
ROIV	\$24.2B	-88.2	-6%	—	-67.6%	1/9	—
INCY	\$22.9B	13.9	31%	35.0%	+26.9%	8/9	—
UTHR	\$22.9B	17.6	19%	42.5%	+2.5%	6/9	—

1-yr returns computed from adjusted price history; peers without a tracked series show —.

29 ANALYST CONSENSUS & ESTIMATES live consensus

Buy

49 Analysts



MEAN TARGET (QTR) \$849.39 18 targets	TARGET VS. PRICE +7.4% last-quarter mean	NEXT REPORT 2026-10-30 street \$16.06
---	--	---

CONSENSUS ESTIMATES	REVENUE MEAN	HIGH / LOW	EPS MEAN	HIGH / LOW	# EPS EST.
FY2026	\$17.56B	\$19.00B / \$15.77B	\$58.55	\$64.88 / \$44.28	15
FY2027	\$18.74B	\$20.16B / \$16.96B	\$62.56	\$67.39 / \$51.54	9
FY2028	\$20.09B	\$22.62B / \$17.65B	\$69.66	\$78.32 / \$61.43	7

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

30 STREET TARGETS & THIRD-PARTY RATING

live targets + composite

Street Price Target — Trajectory

WINDOW	AVG TARGET	VS. PRICE	# TARGETS
Last Month	\$869.75	+10.0%	8
Last Quarter	\$849.39	+7.4%	18
Last Year	\$823.93	+4.2%	72
All Time	\$863.97	+9.3%	153

Rolling mean of published targets vs. last close \$790.74. Aggregated from StreetInsider, Benzinga, Pulse 2.0.

Third-Party Composite Rating


A

DCF5/5ROE4/5ROA5/5DEBT/EQ3/5P/E3/5P/B3/5

Independent quant composite as of 2026-10-16; components scored 1-5 (5 best). Shown for contrast with the InsiderStreet Score — methodologies differ.

31 PRICE PERFORMANCE — INDEXED, 12 MO

live prices · benchmark + sector + peer set



All series indexed to 100 at the start of the window, adjusted closes.

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

TECHNICAL CHART — 6-MONTH DAILY CANDLES, INDICATORS ONsite chart, print edition



Candlesticks with SMA 20/50 overlay, Bollinger (20,2σ) band, volume, and Wilder RSI(14) — computed from live daily OHLCV.

MOVING AVERAGE RIBBON & TRENDsite technicals-tab chart, live indicator history



MOVING AVERAGE	VALUE	DISTANCE	% DISTANCE	SIGNAL
SMA 20	\$764.69	+26.05	+3.41%	Above
SMA 50	\$790.72	+0.02	+0.00%	Above
SMA 200	\$735.17	+55.57	+7.56%	Above
EMA 9	\$769.58	+21.16	+2.75%	Above
EMA 21	\$768.52	+22.22	+2.89%	Above
EMA 50	\$765.86	+24.88	+3.25%	Above
EMA 200	\$728.64	+62.10	+8.52%	Above

Series and readings from the nightly technical-indicator history — identical data to the site's ribbon chart. Supertrend segments colored by direction.

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

32 TECHNICAL POWER SCORE

EDGE · site engine · 76/100 composite

TECHNICAL VERDICT

BULLISH

Power Score +51

21 of 22 indicator votes bullish

Family Scores (site weights)

Trend 30%

Momentum 25%

Volume 20%

Volatility 10%

Patterns 15%

100

90


62

33

50

BULLISH — BUT WHICH WAY IS IT TRENDING?

vote share recomputed weekly, 13 weeks




INDICATOR VOTE GRID

21 bull / 1 bear

● Price vs SMA 20	\$764.69	● Price vs SMA 50	\$790.72	● Price vs SMA 200	\$735.17
● EMA 9/21 Cross	769.6/768.5	● SMA 50/200	Golden	● ADX Direction	ADX 18
● Supertrend	\$733	● Parabolic SAR	\$736	● SMA Slope	0.290
● RSI	57.2	● Stochastic K/D	77/64	● StochRSI K/D	97/90
● Williams %R	-21	● CCI	83	● TSI vs Signal	-3.6
● CMO	14.3	● ROC	7.55%	● OBV Signal	Accum
● Chaikin MF	0.000	● MFI	50	● Force Index	3M
● Elder Ray Bull	35.63				

INDICATOR GAUGES

site technicals-tab style



33 KEY LEVELS & VOLATILITY

live indicator table

LEVEL	VALUE	LEVEL	VALUE
Pivot / R1 / R2	\$799.47 / \$806.36 / \$816.38	S1 / S2	\$789.45 / \$782.56
Bollinger (20,2)	\$713.05 – \$816.33	Squeeze	Off
52-wk range	\$563.30 – \$859.34	Off 52-wk high	-8.0%
ATR (14)	\$21.66 (2.7%)	Historical vol	29.4%

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

34 SEASONALITY — 20-YEAR AVERAGES											live model · win rates shown
+1.5% Jan 45%	+0.6% Feb 60%	+2.3% Mar 62%	+0.7% Apr 45%	+0.9% May 65%	-2.7% Jun 40%	+7.1% Jul 75%	+5.0% Aug 70%	-0.8% Sep 40%	-0.6% Oct 40%	+4.2% Nov 65%	+2.3% Dec 50%

Sample: 20 years — treat short histories as suggestive, not statistical.

35 RISK INDICATORS			computed from live price history
COMPUTED FROM LIVE WEEKLY PRICES			
Weekly volatility (σ , 1y)	REGN	S&P 500	
Best / worst week (1y)	4.51%	1.83%	
Max drawdown (5y, monthly)	+13.6% / -8.4%	—	
1-week VaR (95%)	-56.0%	—	
Beta (5y)	-7.8%	—	
	0.24	1.00	

36 EQUITY WEATHER & MARKET REGIME

EDGE · live weather engine

REGN EQUITY WEATHER (LIVE)

CLOUDY · +1

Trend

Momentum

Volume

Volatility

Breadth

+33

+45

-43

-60

-30

MARKET REGIME (2026-10-16)

NEUTRAL

VIX

DOW THEORY

SPY / QQQ TSI

SECTOR STRENGTH

19.99

Confirmed Bearish


7.2 / 4.7

46/100

Normal

trend strength

breadth average



THIS SPACE INTENTIONALLY LEFT BLANK — THE NEXT SECTION BEGINS ON THE FOLLOWING PAGE

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

38 WEATHER - COMPANY VS INDUSTRY, SECTOR, UNIVERSE

EDGE · live weather engine · Cloudy

OVERALL +0.5 +38.1 vs industry	TREND +33.2 +72.7 vs industry	MOMENTUM +44.9 +93.4 vs industry	VOLUME -43.0 -4.2 vs industry
---	--	---	--

READING	REGN	BIOTECHNOLOGY N=1,668	HEALTHCARE N=5,272	ALL US SYMBOLS N=70,435
Overall	+0.5	-37.6	-24.0	-20.5
Trend	+33.2	-39.5	-25.6	-21.3
Momentum	+44.9	-48.5	-28.5	-15.8
Volume	-43.0	-38.8	-25.0	-3.8

Trend, momentum and volume are computed per company. Volatility and breadth are market-regime values shared by every symbol in the universe, so they are reported once under Market Regime rather than compared here - a company cannot differ from its sector on a constant.

39 EXECUTIVE COMPENSATION


live proxy data · FY2025

EXECUTIVE	TOTAL COMP	STRUCTURE
Daniel P. Van Plew Executive Vice President	\$8.8M	42% equity+incentive
Andrew J. Murphy, Ph.D. Executive Vice Presi	\$8.5M	41% equity+incentive
Joseph J. LaRosa Executive Vice President, G	\$7.5M	36% equity+incentive
Leonard S. Schleifer, M.D., Ph.D. Board co-C	\$7.3M	51% equity+incentive
Christopher Fenimore Executive Vice Presiden	\$7.0M	42% equity+incentive

40 ESG ASSESSMENT

live disclosure-derived scores

PILLAR (LIVE DISCLOSURE SCORES)	SCORE
Environmental	48
Social	47
Governance	55
Composite ESG	50



41 8-K MATERIAL EVENTS

live EDGAR feed

FILED	8-K CONTENTS	ITEMS
2026-10-06	Material Agreement; Earnings Release; Other Events	1.01,2.02,8.01
2026-09-30	Officer/Director Change; Exhibits	5.02,9.01
2026-07-30	Earnings Release; Exhibits	2.02,9.01
2026-07-06	Earnings Release	2.02
2026-06-17	Shareholder Vote	5.07
2026-04-29	Earnings Release; Exhibits	2.02,9.01
2026-04-08	Earnings Release	2.02
2026-01-30	Results of Operations and Financial Condition; Financial Statements an	2.02,9.01

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

42 METHODOLOGY

Methodology. Every figure originates in InsiderStreet's production data layer and is computed deterministically by the same engines that power insiderstreet.ai. This factsheet contains no model-written text. Sections without underlying data are omitted rather than estimated.

43 DISCLOSURES

DISCLOSURES. This document is produced by InsiderStreet.ai from live production data. It is not investment advice, not an offer or solicitation to buy or sell any security, and not a recommendation tailored to any person. Data is sourced as of the dates shown and may no longer be current. InsiderStreet.ai is not a registered investment adviser or broker-dealer. Investing involves risk, including loss of principal. Past performance does not guarantee future results. Do not make any investment decision based on this document. © 2026 InsiderStreet.ai — all rights reserved. Redistribution prohibited.

44 DATA PROVENANCE FOR THIS REPORT sources · coverage · method

DATA DOMAIN	SOURCE	COVERAGE FOR THIS REPORT
Price & volume	market_db.historical_prices	52 rows
Fundamentals	income_statements_annual	6 rows · 2020 to 2025
Reported vs consensus	fact/earnings_calendar	24 rows · 2020-11-05 to 2026-07-30
Analyst estimates	dim/forward_estimates	3 rows · 2026-12-31 to 2028-12-31
Institutional ownership (13F)	holdings_db.institutional_ownership_summary	113 rows · 1998 to 2026
Insider transactions (Form 4)	edgar/form4	12 rows · 2026-10-14
Proposed sales (Form 144)	edgar/form144	1 record
Beneficial ownership (13D/G)	edgar/13dg	4 rows · 2025-06-05 to 2026-04-30
Short-sale volume (FINRA)	edgar/short_volume_daily	60 rows · 2026-07-23 to 2026-10-15
Dark pool (ATS, tier 1)	edgar/darkpool_weekly	12 rows · 2026-06-15 to 2026-08-31
ETF & fund holding	etf_holdings_changelog (30d)	1 record
Peer set	stock_peers_dynamic	8 rows
Industry medians	industry_medians	1 record
Congressional trades	congress_db (House + Senate)	1 record
ESG	fact/esg_disclosures	1 record

Method. Every figure in this factsheet is looked up from a named field computed in code. It contains no model-written text.

Not covered. Short interest as a percent of float and days-to-cover are not in this data set — the short-sale figures above are FINRA volume, a flow, and cannot support squeeze or covering analysis. Options positioning and intraday data are also absent. 13F ownership is filed 45 days after quarter end and congressional trades are disclosed on a lag, so both describe a past position, not a current one.